PDCD1 and non-small cell lung carcinoma: Antithetical results were obtained by Takada et al.—in a cohort of 89 NSCLC patients treated with anti PD-1 therapy, pre-treatment SUVmax values higher than 11.6 correlated with better Objective Response Rate (ORR) (p = 0.0012), although this did not translate into a survival benefit [42].